Oncolytics Biotech Inc.
210-1167 Kensington Crescent
411 articles with Oncolytics Biotech Inc.
Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the first patient was treated in a phase 1 dose escalation study combining pelareorep and carfilzomib with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo®(nivolumab) to treat relapsed multiple myeloma patients.
Oncolytics Biotech® Announces Publication of Positive Clinical Results for Pelareorep in Abstract for ESMO 2018 Congress
Pelareorep and FOLFIRI/B combination shows superior OS & PFS data in KRAS mutant colorectal cancer compared to historical data
Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors Even in the Presence of Neutralizing Antibodies
Oncolytics Biotech® Inc. today announced publication of important research in the peer-reviewed journal Cancer Immunology Research.
Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep
Oncolytics Biotech® Inc. today announced a clinical collaboration with SOLTI, an academic research group dedicated to clinical and translational research in breast cancer.
12/20/2017When considering options in the biotech sector, experts often look more into the major companies providing massive amounts of resources to new candidates.
The appointment fills the vacancy resulting from Mr. Tom Rossi’s resignation from the Board of Directors.
Oncolytics Biotech Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN in Metastatic Breast Cancer
The Letter refers to the proposed use of pelareorep in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative metastatic breast cancer patients in a pivotal phase 3 registration study.
Oncolytics Biotech Establishes Scientific Advisory Board Focused on REOLYSIN Registration Study in Metastatic Breast Cancer
The SAB will provide Oncolytics with significant clinical expertise and experience in breast cancer drug development in both the U.S. and Europe.
Under the terms of The Agreement, Adlai will have exclusive development and commercialization rights to REOLYSIN in China, Hong Kong, Macau, Singapore, South Korea and Taiwan.
Oncolytics Biotech today announced its financial results and operational highlights for the quarter ended September 30, 2017.
"Ms. Brown's wealth of experience in new product launches and market expansion will lend valuable insights as we progress REOLYSIN toward commercialization," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech.
Oncolytics Biotech Announces Successful End-Of-Phase II Meeting With FDA For REOLYSIN In Metastatic Breast Cancer
Oncolytics Biotech To Present REOLYSIN Safety Data In Combination With Chemotherapy At ESMO 2017 Congress